The future of precision medicine part 5: keeping pace with regulation

The first four instalments in this series of articles on precision medicine focused on its challenges and opportunities in general, the importance of large quantities of high quality, diverse data, and some of the particular issues that will be encountered in the translation of research and theory to clinical practice.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Amgen hit with lawsuit over its proposed Opdivo biosimilar

16 September 2026 BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.

Biotech

Australian biotech sues Grail over multi-cancer blood test

15 September 2026 Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational.

Biotech

10x Genomics wins latest round in Parse patent dispute

3 September 2026 Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.

More features

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Beyond the primary patent: How pharma can build competitive barriers

Australian biotech sues Grail over multi-cancer blood test

J&J unit win shuts door on Sandoz generic launch

Abbott clinches 18-country PI in glucose monitoring feud

Sun Pharma import ban back in force after Squires intervention

10x Genomics wins latest round in Parse patent dispute

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

The future of precision medicine part 5: keeping pace with regulation

More on this story

Editor's picks

Editor's picks

More features